多发性骨髓瘤患者骨髓可溶性B细胞成熟抗原表达与靶向B细胞成熟抗原的嵌合抗原受体T细胞疗效相关性的临床分析
该研究纳入29例2018年1月至2021年12月接受人源化抗BCMA CAR-T细胞临床试验的复发/难治多发性骨髓瘤患者,用流式细胞术检测治疗前后骨髓sBCMA表达。结果示20例(68.97%)获总体反应,OR组治疗前sBCMA高于治疗后,OR组治疗前sBCMA低于MR+SD组,sBCMA与CRS、ICANS严重程度无显著相关。结论认为骨髓sBCMA与疗效有关,或可作为疗效预测标志物。
要点
- 29例RRMM患者接受抗BCMA CAR-T治疗2个月,20例(68.97%)获总体反应。
- OR组治疗前骨髓sBCMA高于治疗后,MR+SD组治疗前后无显著差异。
- 治疗前sBCMA在OR组低于MR+SD组,与CRS、ICANS严重程度无显著相关。
核心结论
- 骨髓sBCMA表达与RRMM患者接受BCMA CAR-T细胞治疗的疗效有关,但与不良事件严重程度无显著相关性。
研究设计与样本
- 以2018年1月至2021年12月接受人源化抗BCMA CAR-T细胞临床试验的29例复发/难治MM患者为研究对象。
- 用流式细胞术检测抗BCMA CAR-T细胞治疗前后骨髓sBCMA的表达并进行差异比较。
主要发现
- BCMA CAR-T细胞治疗2个月,20例(68.97%)患者获得总体反应,9例患者仅为病情稳定或微小缓解。
- 20例OR组患者骨髓sBCMA表达治疗前高于治疗后[26 926(18 215, 32 488)ng/L对9 968(6 634, 11 459)ng/L,P<0.001]。
- MR+SD组患者骨髓sBCMA表达治疗前后差异无统计学意义[41 187(33 816, 47 046)ng/L对33 954(31 569, 36 256)ng/L,P=0.145]。
- CAR-T细胞治疗前骨髓sBCMA表达OR组低于MR+SD组患者(P=0.005)。
- 全部29例RRMM患者CAR-T细胞峰值与骨髓sBCMA表达无明显线性相关性(R(2)=0.035,P=0.330)。
临床怎么用
- 作者认为骨髓sBCMA或可作为RRMM患者接受BCMA CAR-T细胞治疗的疗效预测标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The effect of bone marrow soluble B cell maturation antigen (sBCMA) expression on the efficacy and side effects of chimeric antigen receptor (CAR) -modified T-cell-targeting B cell maturation antigen (BCMA) in patients with multiple myeloma (MM) . Methods: This study involved 29 patients with relapsed or refractory MM (RRMM) who received humanized anti-BCMA CAR-T cell clinical trials from January 2018 to December 2021. The expression of sBCMA in bone marrow before and after anti-BCMA CAR-T cell treatment was detected by flow cytometry and compared. Results: ①Two months after BCMA CAR-T cell treatment, 20 patients (68.97%) achieved an overall response (OR), whereas nine patients had stable disease (SD) or miner emission (MR). ②The expression of sBCMA in the bone marrow of 20 patients with OR was higher before treatment than after [26 926 (18 215, 32 488) ng/L vs 9 968 (6 634, 11 459) ng/L; P<0.001]; no significant difference was observed in patients with MR and SD [41 187 (33 816, 47 046) ng/L vs. 33 954 (31 569, 36 256) ng/L; P=0.145]; sBCMA expression in patients with OR before CAR-T cell treatment was lower than in patients with MR and SD (P=0.005). ③No significant linear correlation was found between the peak value of CAR-T cells and sBCMA expression in the bone marrow of all 29 patients with RRMM (R(2)=0.035, P=0.330). ④No significant difference in sBCMA expression was found between grades 0-1 CRS group (13 patients) and grades 2-4 CRS group [16 patients; 32 045 (18 742, 40 801) ng/L vs 29 102 (24 679, 38 776) ng/L, P=0.879], nor between grade 0 ICANS group (22 patients) and grade 1-3 ICANS group [seven patients; 30 073 (19 375, 40 065) ng/L vs 33 816 (22 933, 43 459) ng/L, P=0.763]. Conclusion: sBCMA expression in the bone marrow is related to the efficacy of BCMA CAR-T cell therapy in patients with RRMM, but is not significantly correlated with the severity of adverse events. It may serve as a predictive biomarker for the efficacy of BCMA CAR-T cell therapy in these patients. 目的: 探索多发性骨髓瘤(MM)患者骨髓可溶性B细胞成熟抗原(sBCMA)表达对靶向B细胞成熟抗原(BCMA)的嵌合抗原受体T细胞(CAR-T细胞)治疗疗效及安全性的影响。 方法: 以2018年1月至2021年12月接受人源化抗BCMA CAR-T细胞临床试验的29例复发/难治MM(RRMM)患者为研究对象。流式细胞术检测抗BCMA CAR-T细胞治疗前后骨髓sBCMA的表达并进行差异比较。 结果: ①BCMA CAR-T细胞治疗2个月,20例(68.97%)患者获得总体反应(OR),9例患者仅为病情稳定(SD)或微小缓解(MR)。②20例OR组患者骨髓sBCMA表达治疗前高于治疗后[26 926(18 215, 32 488)ng/L对9 968(6 634, 11 459)ng/L,P<0.001];而MR+SD组患者骨髓sBCMA表达治疗前后差异无统计学意义[41 187(33 816, 47 046)ng/L对33 954(31 569, 36 256)ng/L,P=0.145];CAR-T细胞治疗前骨髓sBCMA表达OR组低于MR+SD组患者(P=0.005)。③全部29例RRMM患者CAR-T细胞峰值与骨髓sBCMA表达无明显线性相关性(R(2)=0.035,P=0.330)。④sBCMA表达水平与CAR-T细胞治疗不良事件严重程度的相关性:0~1级细胞因子释放综合征(CRS)组(13例)与2~4级CRS组(16例)比较骨髓sBCMA表达差异无统计学意义[32 045(18 742, 40 801)ng/L对29 102(24 679, 38 776)ng/L,P=0.879];0级免疫效应细胞相关神经毒性综合征(ICANS)组(22例)与1~3级ICANS组(7例)比较骨髓sBCMA表达差异无统计学意义[30 073(19 375, 40 065)ng/L对33 816(22 933, 43 459)ng/L,P=0.763]。 结论: 骨髓sBCMA表达与RRMM患者接受BCMA CAR-T细胞治疗的疗效有关,但与不良事件严重程度无显著相关性。或可作为RRMM患者接受BCMA CAR-T细胞治疗的疗效预测标志物。.
引用
- Gao SQ, Mu J, Li X, et al. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 38951066. doi:10.3760/cma.j.issn.0253-2727.2023.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。